|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.88 SEK | -1.01% |
|
-3.29% | -23.24% |
| 04-29 | Ziccum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-14 | Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace | CI |
Ziccum AB (publ) reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was SEK 0.638 million compared to SEK 0.009 million a year ago. Net loss was SEK 4.87 million compared to SEK 6.29 million a year ago.
Basic loss per share from continuing operations was SEK 0.35.
| 1st Jan change | Capi. | |
|---|---|---|
| -23.24% | 8.53M | |
| -3.05% | 90.45B | |
| +3.95% | 41.45B | |
| -10.24% | 33.57B | |
| +60.58% | 25.73B | |
| -20.72% | 14.73B | |
| -8.82% | 12.82B | |
| -11.46% | 11.7B | |
| -43.05% | 11.44B | |
| +5.17% | 8.79B |
ZICCUM AB 
